Core Viewpoint - The article discusses the public's concerns regarding the quality of drugs under the centralized procurement policy in China, emphasizing the need for transparency and trust in the system [2][11]. Group 1: Public Concerns and Trust Issues - Many patients express a preference for imported drugs over those available through centralized procurement, fearing that lower prices equate to lower quality [4][5]. - A significant number of patients are skeptical about the effectiveness of centralized procurement drugs, with some stating they would rather pay for imported options [5][6]. - The article highlights that the centralized procurement policy has saved over 400 billion yuan in medical insurance funds, which has reduced the financial burden on the state [4]. Group 2: Recommendations for Improvement - Zhang Weilin suggests that improving the transparency of drug procurement data and ensuring accurate communication of information can help alleviate public concerns [14]. - Establishing a supervision platform for regular quality checks of centralized procurement drugs is recommended to maintain standards and build trust [17][18]. - The article advocates for a mechanism to ensure that price reductions do not compromise drug quality, emphasizing the importance of consistent evaluations and regulatory oversight [16][17]. Group 3: Comparative Insights - The article compares China's approach to drug pricing and procurement with that of other countries, noting that countries like the United States and India have different policies that allow for lower drug prices post-patent expiration [9][10]. - It is mentioned that while India allows "strong imitation" of drugs even during patent protection, China respects intellectual property rights and supports innovation through government policies [10]. Group 4: Clinical Experiences - The author shares personal experiences of patients expressing doubts about centralized procurement drugs, indicating a need for healthcare professionals to advocate for the quality of these medications [5][6]. - The article notes that some patients are reassured when they learn that healthcare providers also use centralized procurement drugs without issues [7].